Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Surv...(g on treatment had to do withaffording h...),Health

Date:5/28/2008

g on treatment had to do with affording her medicine, a barrier also noted by 27 percent of people surveyed.(1) "The day I learned I had MS, I vowed to do everything I could to fight the disease. So when my doctor recommended treatment, I followed his advice," Jillian said. "But my commitment was challenged when I recently lost my insurance. With only three doses of my medication left and no possible way to pay for another prescription, I was going to lose the one thing that was going well for me. My doctor told me that I could continue receiving my medicine through a company-sponsored patient assistance program. It's one of the benefits of the BETAPLUS(TM)(b) program that patients on Betaseron can sign up for. It was a great relief and allowed me to continue my fight against the disease."

Participants in the survey noted that worries about how to store medicine while traveling or away from home (9 percent) also diminish their commitment to treatment. Factors cited by survey participants that make it easier to stay on medication include family support (84 percent), drug company-sponsored support such as materials or Web sites (60 percent) and a nurse provided by a drug company (43 percent).(1)

The survey was conducted by Russell Research and funded by Bayer HealthCare Pharmaceuticals Inc.(1)

About Betaseron

Betaseron (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

A number of factors have been shown to influence a person's perceived comfort and satisfaction associated with MS medications, including number of injections, product formulation and patient support. Betaseron therapy requires half as many injections as Copaxone(R)* (glatiramir acetate).(
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
2. Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD
3. Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD
4. Study: Doctors Significantly Less Likely to Provide Women with Treatments to Prevent Heart Attacks
5. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Paramed Systems Achieves Significant Business Milestone in the Offshore Oil and Gas Evacuation Market
8. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
9. U.S. Patent Office Allows Another Significant VNUS Patent
10. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
11. Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence